Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Ironwood Pharma (IRWD) Tops Q2 EPS by 12c, Updates Guidance
August 5, 2021 7:58 AM EDTIronwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.34, $0.12 better than the analyst estimate of $0.22. Revenue for the quarter came in at $104.1 million versus the consensus estimate of $93.1 million.
GUIDANCE:
Ironwood Pharma sees FY2021 revenue of $390-410 million, versus the consensus of... More
